NRx Ebitda from 2010 to 2024

NRXPW Stock  USD 0.05  0  1.96%   
NRx Pharmaceuticals EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -31.5 M in 2024. During the period from 2010 to 2024, NRx Pharmaceuticals EBITDA regression line of quarterly data had mean square error of 480.1 T and geometric mean of  566,542. View All Fundamentals
 
EBITDA  
First Reported
2017-12-31
Previous Quarter
-7 M
Current Value
-1.6 M
Quarterly Volatility
13.1 M
 
Covid
Check NRx Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRx Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 K, Interest Expense of 114 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRx financial statements analysis is a perfect complement when working with NRx Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NRx Pharmaceuticals Correlation against competitors.
For more information on how to buy NRx Stock please use our How to Invest in NRx Pharmaceuticals guide.

Latest NRx Pharmaceuticals' Ebitda Growth Pattern

Below is the plot of the Ebitda of NRx Pharmaceuticals over the last few years. It is NRx Pharmaceuticals' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRx Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

NRx Ebitda Regression Statistics

Arithmetic Mean(16,355,187)
Geometric Mean566,542
Coefficient Of Variation(169.78)
Mean Deviation21,904,975
Median82,412
Standard Deviation27,768,175
Sample Variance771.1T
Range93.1M
R-Value(0.65)
Mean Square Error480.1T
R-Squared0.42
Significance0.01
Slope(4,032,680)
Total Sum of Squares10795T

NRx Ebitda History

2024-31.5 M
2023-30 M
2022-39.8 M
2021-93 M
2020-51.7 M
2019 -6262.38

About NRx Pharmaceuticals Financial Statements

NRx Pharmaceuticals investors use historical fundamental indicators, such as NRx Pharmaceuticals' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NRx Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-30 M-31.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NRx Stock Analysis

When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.